Navigation Links
Presentations of Cempra Pharmaceutical's CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
Date:10/28/2009

ighly correlated susceptibility results across multiple S. aureus strains.

An oral presentation, scheduled at 3:30 p.m. EDT, October 31, presents evidence, through a pharmacokinetic-pharmacodynamic model based on drug clearance data from 69 healthy subjects, that a loading dose of CEM-102 on the first day of treatment can generate significantly better antibacterial effects compared to regimens without a loading dose. The analysis showed that a loading dose of at least 1,200 mg twice-daily on the first treatment day followed by 600 mg twice-daily on subsequent days optimized the antibacterial effect of CEM-102. This provides the rationale for the unique loading dose regimen employed in the ongoing Phase 2/3 clinical trial to minimize bacterial resistance and optimize efficacy.

"Antibiotic-resistant S. aureus strains are an increasing therapeutic problem both in the community as well as in the hospital setting," said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra Pharmaceuticals. "New treatment alternatives are in great need, particularly agents that are safe, administered orally, and can prevent patients from being admitted to the hospital. The potent anti-staph activity of CEM-102, its long safety record and low incidence of resistance make it a highly promising anti-MRSA drug candidate."

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing i
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
2. Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
3. IDM Pharma Announces Upcoming Clinical Data Presentations
4. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
10. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 1, 2014 The global high ... marked by the ,Threat of Obsolescence, wherein technologies as ... rapidly. Pharmaceutical and biotechnology companies as well as academic ... content screening as a powerful research tool in drug ... fastest-growing segment in the high content screening market. In ...
(Date:10/1/2014)... 1, 2014   Plexus Information Systems, Inc. ... Information Management Systems (AIMS), announced a partnership with ... wholly owned subsidiary of Quality Systems, Inc. and ... connectivity solutions.  Logo - ... This partnership extends the NextGen Healthcare ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... provider for the medical industries, announced today the expansion of its ... New York City . genae Americas was incorporated in 2011. ... centered in one of the highest concentrations of medical innovation and ... , President at genae Americas. "The expansion of genae from ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3genae Opens Offices in New York City 2
... SILVER SPRING, Md., June 8, 2011 The Food and ... containing 80 mg of simvastatin — the highest approved dose ... of the risk of muscle injury. (Logo:   ... only be used by patients who have been taking it ...
... Merz Pharmaceuticals today announced that new data on ... from accessory (complexing) proteins, will be presented at ... of Parkinson,s Disease and Movement Disorders in Toronto, ... XEOMIN were safe and effective in the treatment ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Limit Use of 80 mg Simvastatin 2New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS) 2New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS) 3
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... roses -- literally -- may face an increased risk of dying ... study of over 3,000 older Americans, researchers found those who were ... more than three times as likely to die in the next ... In fact, anosmia -- the inability to distinguish odors -- was ...
(Date:10/1/2014)... University of Adelaide have developed a model that could ... outcome from treatment - from their very first psychotic ... of factors, including clinical symptoms, cognitive abilities, MRI scans ... blood. , Speaking in the lead up to World ... Psychiatry , Professor Bernhard Baune , says ...
(Date:10/1/2014)... the brain of a rat and a robot could ... QUT leading robotics researcher. , Dr Michael Milford ... study uses new computer algorithms to enable robots to ... "This is a very Frankenstein type of project," Dr ... thing together because we,re taking the eyes of a ...
(Date:10/1/2014)... people to keep their "eyes on the prize" may ... walking, staying focused on a specific target ahead can ... people walk there faster, psychology researchers have found. Their ... around the environment naturally, offers a new strategy to ... interested in exercise if physical activity seems daunting, which ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... the #1 co-ed,fitness club chain in the world, has ... has clubs operating in 46 states, Canada and Australia,serving ... other well-known fitness chains have recently scaled back their,expansion ... grow at,an impressive rate. In fact, in the past ...
... the eye region is also useful when trying to spot fatigue ... or less tired? Focus on the area around your eyes, a ... your age and level of fatigue. , When asked to ... looked at the eye region almost half the time, researchers ...
... profound impact on this country,s psyche. Eight years after ... events affected us. A number of studies have shown ... the terrorist attacks experienced heightened levels of stress and ... Research has also indicated that elevated levels of stress ...
... PARK, N.J. and NEW YORK, Feb. 2 HLTH Corporation ... subsidiary, WebMD Health Corp. (Nasdaq: WBMD ), today ... the three months ended December 31, 2008 at approximately 4:00 ... will host a conference call at 4:45 pm (ET) on ...
... SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced ... Ph.D., M.B.A., to serve as president and chief executive officer. ... SCOLR Pharma board of directors since August 2007.Michael N. Taglich, ... very pleased that Dr. Morra has agreed to become SCOLR ...
... (TFAH) strongly supports President Obama,s call for a "complete ... outbreak of Salmonella tied to peanut butter ... Salmonella outbreaks in 2008 highlight the need ... released a comprehensive report, Fixing Food Safety: Protecting ...
Cached Medicine News:Health News:Anytime Fitness Opens 1,000th Club 2Health News:Anytime Fitness Opens 1,000th Club 3Health News:When Gauging Age, the Eyes Have It 2Health News:Driving under the influence (of stress): Regional effects of 9/11 attacks on driving 2Health News:HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 3Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 2Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 3
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
Lancets are the fine needles used with a lancing device to draw a blood sample for glucose testing. To make testing less painful, we developed lancets with extra-thin tips....
... The HEMOCHRON Jr. Signature Microcoagulation System ... bedside with just one drop (.015cc) of ... a portable, hand-held, battery-operated instrument, the HEMOCHRON ... capabilities and print (optional) both patient and ...
Inquire...
Medicine Products: